AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11854120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrillin-1 genotype (2-3 genotype)
Number of subjects: 145
Study 11854120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrillin-1 genotype
Number of subjects: 145
Study 10334524 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent drugs (trimetrexate, melphalan, amonafide, carboplatin, or elsamitrucin) followed by CAF
Number of subjects: 365
Study 10334524 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 365
Study 10334524 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent drugs followed by CAF
Number of subjects: 365
Study 10334524 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 365
Study 8960857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive drug therapy
Number of subjects: 950
Study 8960857 — intervention group
Group type: COMPARATOR
Intervention: Moderate antihypertensive drug therapy
Number of subjects: 950
Study 8960857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (calcium channel blocker)
Number of subjects: 950
Study 8960857 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin‐converting‐enzyme inhibitor)
Number of subjects: 950
Study 8960857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive therapy
Number of subjects: 950
Study 8960857 — intervention group
Group type: COMPARATOR
Intervention: Moderate antihypertensive therapy
Number of subjects: 950
Study 1661765 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg/day)
Number of subjects: 14
Study 1661765 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg/day)
Number of subjects: 14
Study 1661765 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (240 mg/day)
Number of subjects: 14
Study 1661765 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 14
Study 6761595 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFV (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine)
Number of subjects: 236
Study 6761595 — intervention group
Group type: COMPARATOR
Intervention: CD (carminomycin, dibromodulcitol)
Number of subjects: 236
Study 6761595 — intervention group
Group type: COMPARATOR
Intervention: CMFV to CD crossover
Number of subjects: 236
Study 6761595 — intervention group
Group type: COMPARATOR
Intervention: CD to CMFV crossover
Number of subjects: 236
Study 6761595 — intervention group
Group type: COMPARATOR
Intervention: CD combination
Number of subjects: 236
Study 30415307 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness Index of antibiotic resistance
Number of subjects: 48
Study 30415307 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic conservation practices
Number of subjects: 48
Study 30415307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical awareness of veterinarians
Number of subjects: 48
Study 29415687 — intervention group
Group type: EXPERIMENTAL
Intervention: STAK-D intervention
Number of subjects: 13
Study 26691608 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based child oral hygiene program
Number of subjects: 120
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.125 mg/day
Number of subjects: 631
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin ≥ 0.25 mg/day
Number of subjects: 631
Study 24067296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin overall
Number of subjects: 631
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin for cardiovascular causes
Number of subjects: 631
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin for heart failure causes
Number of subjects: 631
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin for unstable angina causes
Number of subjects: 631
Study 24067296 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin in younger patients
Number of subjects: 631
Study 23257098 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Lung Lavage (WLL)
Number of subjects: 70
Study 23257098 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 20854139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of ≥1 hypertension medications
Number of subjects: 2156
Study 20854139 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (all medications ingested upon awakening)
Number of subjects: 2156
Study 17931286 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal nutrition intervention (personalized, face-to-face feedback with educational materials)
Number of subjects: 203
Study 17931286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 203
Study 16301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution at PaCO2 of 40 mmHg
Number of subjects: 30
Study 16301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution at PaCO2 of 30 mmHg
Number of subjects: 30
Study 16301225 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal Doppler at PaCO2 of 40 mmHg
Number of subjects: 30
Study 16301225 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal Doppler at PaCO2 of 30 mmHg
Number of subjects: 30
Study 12077744 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with type 2 diabetes
Number of subjects: 70
Study 12077744 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients with type 2 diabetes
Number of subjects: 70
Study 11154484 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Balloon Dilation (EBD)
Number of subjects: 34
Study 11154484 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 34
Study 11154484 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Balloon Dilation (EBD) and Endoscopic Sphincterotomy (EST)
Number of subjects: 34
Study 9596232 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol intake (<50 g/d)
Number of subjects: 0
Study 9596232 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption (>=100 g/d)
Number of subjects: 0
Study 9596232 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol intake
Number of subjects: 0
Study 9596232 — intervention group
Group type: EXPERIMENTAL
Intervention: Light drinking
Number of subjects: 0
Study 9596232 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional drinking (less than once a week)
Number of subjects: 0
Study 7508804 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost for 6 h per day over 14-21 days
Number of subjects: 713
Study 7508804 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative treatment
Number of subjects: 713
Study 7508804 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost
Number of subjects: 713
Study 3128439 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (3 mg/h)
Number of subjects: 12
Study 3128439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 12
Study 20804228 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history (FHx) collection
Number of subjects: 0
Study 20804228 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive interventions (mammography and fecal occult blood testing)
Number of subjects: 0
Study 20804228 — intervention group
Group type: EXPERIMENTAL
Intervention: FHx-based risk information
Number of subjects: 0
Study 20804228 — intervention group
Group type: COMPARATOR
Intervention: FHx-based breast cancer risk information
Number of subjects: 0
Study 720134 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea preparations under occlusive dressings
Number of subjects: 35
Study 31392958 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple dressing
Number of subjects: 394
Study 31392958 — intervention group
Group type: EXPERIMENTAL
Intervention: Glue-as-a-dressing (tissue adhesive)
Number of subjects: 394
Study 31392958 — intervention group
Group type: EXPERIMENTAL
Intervention: No dressing
Number of subjects: 394
Study 31392958 — intervention group
Group type: COMPARATOR
Intervention: All dressing strategies
Number of subjects: 394
Study 31392958 — intervention group
Group type: COMPARATOR
Intervention: SSI questionnaire
Number of subjects: 394
Study 29553965 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position with ergonomic ankle support
Number of subjects: 168
Study 29553965 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group B (semirecumbent)
Number of subjects: 168
Study 29553965 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group A (unsupported squatting)
Number of subjects: 168
Study 27356083 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 20 mg/kg/d + ARA 40 or 60 mg/kg/d + ARA 120 mg/kg/d
Number of subjects: 30
Study 24512385 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg/day
Number of subjects: 28
Study 24512385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21584922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive subcutaneous insulin protocol
Number of subjects: 65
Study 21584922 — intervention group
Group type: COMPARATOR
Intervention: Standard care with sliding scale insulin
Number of subjects: 65
Study 20215786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with etoposide, Adriamycin and cisplatin (EAP)
Number of subjects: 309
Study 20215786 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (control group)
Number of subjects: 309
Study 20215786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with EAP
Number of subjects: 309
Study 17469888 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 387
Study 17469888 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment as usual
Number of subjects: 387
Study 15960083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile signals administered to the treatment group to indicate the arrival and location of interrupting tasks.
Number of subjects: 61
Study 15960083 — intervention group
Group type: COMPARATOR
Intervention: Control participants had to remember to visually check for the interrupting tasks.
Number of subjects: 61
Study 12360175 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 29
Study 12360175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 29
Study 12360175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both atorvastatin and fenofibrate
Number of subjects: 29
Study 10432959 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 400 mg per day for 14 days followed by 500 mg calcium carbonate per day for 76 days, repeated for one year
Number of subjects: 32
Study 10432959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7672148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 96
Study 7672148 — intervention group
Group type: COMPARATOR
Intervention: Subzonal insemination (SUZI)
Number of subjects: 96
Study 2341204 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy instructional condition
Number of subjects: 0
Study 2341204 — intervention group
Group type: COMPARATOR
Intervention: Nonexpectancy instructional condition
Number of subjects: 0
Study 6936978 — intervention group
Group type: COMPARATOR
Intervention: 3 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen) immediately preseasonal
Number of subjects: 70
Study 6936978 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen)
Number of subjects: 70
Study 6936978 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 injections of a 7 grass pollen extract (semi‐depot, Allpyral)
Number of subjects: 70
Study 6936978 — intervention group
Group type: COMPARATOR
Intervention: 3 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen)
Number of subjects: 70
Study 31430749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical or segmental dystonia diagnosis
Number of subjects: 227
Study 31430749 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual form of thumb flexion dystonia
Number of subjects: 227
Study 28624819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin 2 g
Number of subjects: 100
Study 28624819 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control group)
Number of subjects: 100
Study 25657052 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Classrooms intervention (8-week classroom-based intervention)
Number of subjects: 0
Study 25657052 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' perceptions of the intervention
Number of subjects: 0
Study 25657052 — intervention group
Group type: EXPERIMENTAL
Intervention: Students' enjoyment of the programme
Number of subjects: 0
Study 24680234 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, 5-session, problem-focused couple therapy for depression
Number of subjects: 35
Study 23015558 — intervention group
Group type: EXPERIMENTAL
Intervention: ASR femoral component
Number of subjects: 19
Study 19679248 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based therapy
Number of subjects: 2073
Study 19679248 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine-based therapy
Number of subjects: 2073
Study 19679248 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 2073
Study 19679248 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of heart rate (HR)
Number of subjects: 2073
Study 17236918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prophylactic antibiotics (penicillin or clindamycin for penicillin-allergic subjects)
Number of subjects: 118
Study 17236918 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (0.9% saline)
Number of subjects: 118
Study 15051598 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g MCTs (66% 8:0 and 34% 10:0)
Number of subjects: 17
Study 15051598 — intervention group
Group type: COMPARATOR
Intervention: high-oleic sunflower oil (89.4% 18:1)
Number of subjects: 17
Study 12200551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 500
Study 12200551 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation
Number of subjects: 500
Study 10535880 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (3 MU 3 times weekly) for 24 months
Number of subjects: 53
Study 10535880 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of interferon
Number of subjects: 53
Study 7594123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering diets (30%, 26%, 22%, and 18% of energy from fat; 300, 200, 100, and 100 mg cholesterol)
Number of subjects: 365
Study 7594123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering diets
Number of subjects: 365
Study 2215560 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of hemoglobin A1c levels (n = 115)
Number of subjects: 240
Study 2215560 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 107)
Number of subjects: 240
Study 361162 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 137
Study 361162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 31816598 — intervention group
Group type: EXPERIMENTAL
Intervention: Control plus exercise
Number of subjects: 19
Study 31816598 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (SR)
Number of subjects: 19
Study 31816598 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 31816598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction plus exercise
Number of subjects: 19
Study 29334292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial therapy (3 sessions, 60 min each)
Number of subjects: 16
Study 27194235 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic irrigation using the Ashong colonic irrigation apparatus (ACIA), performed twice daily for 6 consecutive days per week for 1-4 weeks.
Number of subjects: 18
Study 25449510 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical pacing
Number of subjects: 188
Study 25449510 — intervention group
Group type: COMPARATOR
Intervention: Septal pacing
Number of subjects: 188
Study 22116114 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy
Number of subjects: 95
Study 22116114 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher class pain medication
Number of subjects: 95
Study 20205646 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 20205646 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 20205646 — intervention group
Group type: COMPARATOR
Intervention: Cyclooxygenase-2 inhibitors
Number of subjects: 0
Study 17646669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab
Number of subjects: 3386
Study 17646669 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3386
Study 15647216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 0
Study 12173840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (CCC)
Number of subjects: 40
Study 12173840 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (CBC)
Number of subjects: 40
Study 10461288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lead unipolar system (RV-CAN)
Number of subjects: 17
Study 10461288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lead unipolar system with additional IVC lead (RV-CAN + IVC)
Number of subjects: 17
Study 7606425 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation (IDEOS) containing 500 mg calcium and 400 IU vitamin D3, taken as one tablet twice daily for six months
Number of subjects: 91
Study 7606425 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of 8 drops of vitamin D3 (800 IU/day) and one calcium carbonate 500 mg tablet twice daily for six months
Number of subjects: 91
Study 2120785 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB), n = 58
Number of subjects: 110
Study 2120785 — intervention group
Group type: COMPARATOR
Intervention: Dietary control, n = 52
Number of subjects: 110
Study 91886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iodised oil
Number of subjects: 0
Study 91886 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 0
Study 30985694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral rectus sheath block (RSB) using 40 mL of 0.375% ropivacaine
Number of subjects: 46
Study 30985694 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving RSB using 40 mL of normal saline
Number of subjects: 46
Study 28333021 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Trastuzumab (group 1)
Number of subjects: 68
Study 28333021 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (group 2)
Number of subjects: 68
Study 26036453 — intervention group
Group type: EXPERIMENTAL
Intervention: SIgA response to performance or interpersonal stressors
Number of subjects: 82
Study 26036453 — intervention group
Group type: EXPERIMENTAL
Intervention: SIgA
Number of subjects: 82
Study 26036453 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in SIgA over time
Number of subjects: 82
Study 26036453 — intervention group
Group type: COMPARATOR
Intervention: Cortisol and sAA
Number of subjects: 82
Study 24112545 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain helical Tomotherapy with integrated boost (30 Gy in 10 fractions, 50 Gy boost to brain metastases, hippocampal-sparing)
Number of subjects: 0
Study 24112545 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole brain radiotherapy (30 Gy in 10 fractions)
Number of subjects: 0
Study 24112545 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain helical Tomotherapy with integrated boost
Number of subjects: 0
Study 24112545 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole brain radiotherapy
Number of subjects: 0
Study 21377899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful learning condition
Number of subjects: 32
Study 21377899 — intervention group
Group type: COMPARATOR
Intervention: Mindless learning condition
Number of subjects: 32
Study 19920749 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 9
Study 19920749 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (placebo control)
Number of subjects: 9
Study 16487501 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIA using morphine
Number of subjects: 45
Study 16487501 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIA using tramadol
Number of subjects: 45
Study 16487501 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIA using tramadol with lornoxicam
Number of subjects: 45
Study 12620951 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 micro g x kg(‐1) iv followed by a continuous infusion of 0.2 to 0.5 micro g x kg(‐1) x min(‐1))
Number of subjects: 40
Study 12620951 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (0.25 micro g x kg(‐1) x min(‐1) iv and alfentanil iv)
Number of subjects: 40
Study 11189097 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 18882
Study 11189097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18882
Study 9345173 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with high energy groundnut biscuits (4.3 MJ/day) for about 20 weeks before delivery
Number of subjects: 2047
Study 9345173 — intervention group
Group type: COMPARATOR
Intervention: Control group (after delivery)
Number of subjects: 2047
Study 8155388 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 60 mg
Number of subjects: 30
Study 8155388 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 300 mg
Number of subjects: 30
Study 3279769 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.8 micrograms per day)
Number of subjects: 27